Stock TNYA TENAYA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Tenaya Therapeutics, Inc.

Equities

TNYA

US87990A1060

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
4.31 USD +2.13% Intraday chart for Tenaya Therapeutics, Inc. -0.23% +33.02%
20/03 Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $18 From $19, Maintains Buy Rating MT
19/03 North American Morning Briefing : Stock Futures -2- DJ

Evolution of the average Target Price on Tenaya Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

82f44ae37ca11632deb3.U7u2jm7xgsaaVrmzXKtO4dSLafp0Url2CGSDmOY79F0.IOLO4BuQ3b_2BfLKMdN-zKTlMKxEBdg5W1XSrI9YkGoH9PXAF7b686978A~758e38e931e09384f97f5e3169a36a4f

Analyst Recommendations on Tenaya Therapeutics, Inc.

Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $18 From $19, Maintains Buy Rating MT
Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $17 From $18, Keeps Buy Rating MT
Morgan Stanley Adjusts Price Target on Tenaya Therapeutics to $14 From $13, Keeps Overweight Rating MT
Chardan Trims Price Target on Tenaya Therapeutics to $23 From $24, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Tenaya Therapeutics to $18 From $25, Maintains Buy Rating MT
Chardan Cuts Price Target on Tenaya Therapeutics to $24 From $28, Keeps Buy Rating MT
Analysis-Biotech IPOs to bloom with spotlight on startups with human trial data RE
Morgan Stanley Adjusts Price Target on Tenaya Therapeutics to $13 From $15, Maintains Overweight Rating MT
Chardan Trims Price Target on Tenaya Therapeutics to $28 From $30, Affirms Buy Rating MT
Canaccord Genuity Starts Tenaya Therapeutics at Buy With $21 Price Target MT
Chardan Research Trims Tenaya Therapeutics' Price Target to $30 From $31, Maintains Buy Rating MT
HC Wainwright Starts Tenaya Therapeutics at Buy With $25 Price Target MT
Morgan Stanley Lowers Tenaya Therapeutics' Price Target to $15 From $19, Maintains Overweight Rating MT
Morgan Stanley Adjusts Tenaya Therapeutics' Price Target to $19 from $31, Keeps Overweight Rating MT
TENAYA THERAPEUTICS : Chardan Starts Tenaya Therapeutics at Buy with $37 Price Target on Heart Disease Drugs' Potential MT
TENAYA THERAPEUTICS : Cowen Starts Tenaya Therapeutics at Outperform MT
TENAYA THERAPEUTICS : Morgan Stanley Initiates Coverage on Tenaya Therapeutics With Overweight Rating, $31 Price Target MT
TENAYA THERAPEUTICS : Piper Sandler Starts Tenaya Therapeutics at Overweight With $40 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.31 USD
Average target price
19.43 USD
Spread / Average Target
+350.78%
High Price Target
40 USD
Spread / Highest target
+828.07%
Low Price Target
7 USD
Spread / Lowest Target
+62.41%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Tenaya Therapeutics, Inc.

Canaccord Genuity
Morgan Stanley
Chardan Research
HC Wainwright
Piper Sandler
Chardan
Cowen

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TNYA Stock
  4. Consensus Tenaya Therapeutics, Inc.